Eosinophil percentage and platelet counts: Association with in-hospital mortality in ST-segment elevated myocardial

Mahtab Mashayekhi1, Mahdokht Rezaei1, Abbas Allami1

  • 1Boali Hospital, Qazvin University of Medical Sciences, Qazvin, Iran.

ARYA Atherosclerosis
|March 19, 2025
PubMed

Insights

Platelet count and eosinophil percentage are significant indicators for ST-segment elevation myocardial infarction (STEMI) prognosis. Higher platelet counts and specific eosinophil levels correlate with in-hospital mortality and ejection fraction in STEMI patients.

Area of Science:

  • Cardiology
  • Hematology
  • Clinical Pathology

Background:

  • ST-segment elevation myocardial infarction (STEMI) arises from coronary artery blockages.
  • Eosinophils have a complex role in STEMI, influencing thrombus formation and tissue healing.
  • Understanding prognostic markers is crucial for managing STEMI patients.

Purpose of the Study:

  • To investigate the association between eosinophil percentage and platelet counts with in-hospital prognosis in STEMI patients.
  • To determine the predictive value of these markers for mortality and left ventricular ejection fraction (LVEF).

Main Methods:

  • A cross-sectional study of 100 STEMI patients (age ≥18) was conducted.
  • Data collected included demographic, clinical, and laboratory findings, focusing on eosinophil percentage and platelet counts.
  • In-hospital outcomes such as mortality, arrhythmia, and LVEF were recorded and analyzed.

Main Results:

  • A significant correlation was observed between eosinophil percentage and mortality (p=0.032).
  • Platelet count also showed a significant association with mortality (p=0.008).
  • Eosinophil percentage was significantly related to ejection fraction (p<0.001).

Conclusions:

  • Platelet count is a significant prognostic indicator for in-hospital outcomes in STEMI, indicating increased mortality risk.
  • Eosinophil percentage demonstrates a notable relationship with ejection fraction in STEMI patients.
  • These findings highlight potential biomarkers for risk stratification in STEMI management.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...